Company intelligence / Profile preview

Intronn

Seongnam-si, Gyeonggi-do, South Koreaprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

iNtRON Biotechnology has developed first-in-class bacteriophage and endolysin-based therapeutics targeting antibiotic-resistant bacteria, with clinical-stage assets in infectious disease. The company also commercializes diagnostic kits, especially PCR kits for infectious diseases in both human and animal health. Its lead asset SAL200 was outlicensed to Roivant for further development[3][4].

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Bacteriophage therapySmall moleculeBiological products (including endolysin-based agents)
Industry: Biotech

Partnerships

Roivant Sciences – acquired rights to SAL200, a lead bacteriophage-derived therapeutic agent[3]Multiple overseas licensing partners for animal health phage products[3]Diagnostic kit distribution partners globally[3]

Beyond the preview

Go deeper on Intronn.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intronn.

Explore the full profile